Sarepta Therapeutics, Inc. faced a setback in its gene therapy trial, causing a 40% stock drop and raising safety concerns. The company's future depends on transparent communication and rebuilding trust. Despite challenges, its market position and pipeline potential remain strong.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing